
Corey A Siegel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3468318/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Office-Based, Point-of-Care Test Predicts Treatment Outcomes With Community-Based Pelvic Floor Physical Therapy in Patients With Chronic Constipation. Clinical Gastroenterology and Hepatology, 2023, 21, 1082-1090.	4.4	9
2	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 126-135.	4.4	32
3	Poor Sleep in Inflammatory Bowel Disease Is Reflective of Distinct Sleep Disorders. Digestive Diseases and Sciences, 2022, 67, 3096-3107.	2.3	10
4	Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 379-388.	1.3	4
5	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. Digestive Diseases and Sciences, 2022, , 1.	2.3	0
6	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	4.4	9
7	Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection. Crohn's & Colitis 360, 2022, 4, .	1.1	1
8	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open, 2022, 12, e057656.	1.9	17
9	The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 35-53.	4.5	10
10	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.4	3
11	Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology, 2022, 163, 204-221.	1.3	32
12	Hyperbaric Oxygen as Successful Monotherapy for a Severe Ulcerative Colitis Flare. Inflammatory Bowel Diseases, 2022, 28, 1474-1475.	1.9	3
13	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1443-1451.	1.9	18
14	Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review. Digestive Diseases and Sciences, 2021, 66, 843-854.	2.3	5
15	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 839-841.e2.	4.4	15
16	Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 403-405.	4.4	17
17	OUP accepted manuscript. International Journal for Quality in Health Care, 2021, 33, ii40-ii47.	1.8	8
18	SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021, 70. 635-640.	12.1	173

#	Article	IF	CITATIONS
19	Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	4
20	Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. Journal of Medical Internet Research, 2021, 23, e15946.	4.3	9
21	Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process. Inflammatory Bowel Diseases, 2021, , .	1.9	4
22	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014-2025.	0.4	93
23	Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease. Gastroenterology, 2021, 161, 2041-2043.e1.	1.3	27
24	Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors. Scandinavian Journal of Pain, 2021, 21, 283-295.	1.3	4
25	Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn's Disease. Crohn's & Colitis 360, 2021, 3, .	1.1	3
26	Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2459-2464.	0.4	3
27	Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2410-2418.	0.4	12
28	Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study. Inflammatory Bowel Diseases, 2021, , .	1.9	2
29	A pilot feasibility trial of cognitive–behavioural therapy for insomnia in people with inflammatory bowel disease. BMJ Open Gastroenterology, 2021, 8, e000805.	2.7	11
30	Patients' Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications. Inflammatory Bowel Diseases, 2020, 26, 141-146.	1.9	10
31	Identifying Patients With Inflammatory Bowel Diseases atÂHigh vs Low Risk of Complications. Clinical Gastroenterology and Hepatology, 2020, 18, 1261-1267.	4.4	22
32	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 669-681.	3.7	48
33	Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic. Inflammatory Bowel Diseases, 2020, 26, e137-e137.	1.9	1
34	A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. Alimentary Pharmacology and Therapeutics, 2020, 52, 955-963.	3.7	15
35	Systems-Based Strategies to Consider Treatment Costs in Clinical Practice. Clinical Gastroenterology and Hepatology, 2020, 18, 1010-1014.	4.4	14
36	A qualitative inquiry into patients' perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases. Quality of Life Research, 2020, 29, 2403-2414.	3.1	2

#	Article	IF	CITATIONS
37	Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway. Clinical Gastroenterology and Hepatology, 2020, 18, 2645-2649.e4.	4.4	15
38	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2952-2961.e8.	4.4	48
39	Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States. Clinical and Translational Gastroenterology, 2020, 11, e00128.	2.5	35
40	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2526-2534.e9.	4.4	45
41	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	1.3	185
42	Systematic review: hepatosplenic Tâ€cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Alimentary Pharmacology and Therapeutics, 2020, 51, 527-533.	3.7	34
43	A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15994.	1.0	8
44	Management of Inflammatory Bowel Disease With Telemedicine. Gastroenterology and Hepatology, 2020, 16, 526-528.	0.1	0
45	Defining Failure of Medical Therapy for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 74-77.	1.9	22
46	Prognosticating the Course of Inflammatory Bowel Disease. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 395-404.	1.4	15
47	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflammatory Bowel Diseases, 2019, 25, e143-e145.	1.9	13
48	Risks and Side Effects of Medical Therapy. , 2019, , 125-132.		1
49	Deâ€escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. GastroHep, 2019, 1, 108-117.	0.6	3
50	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1655-1668.e3.	4.4	214
51	Challenges in IBD Research: Precision Medicine. Inflammatory Bowel Diseases, 2019, 25, S31-S39.	1.9	67
52	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory Bowel Diseases, 2019, 25, 1854-1861.	1.9	11
53	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2497-2505.e1.	4.4	44
54	Placing Value on Telemedicine for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2019, 114, 382-383.	0.4	8

#	Article	IF	CITATIONS
55	ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2019, 114, 384-413.	0.4	933
56	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1533-1540.e2.	4.4	60
57	Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?. Current Pharmaceutical Design, 2019, 25, 64-68.	1.9	7
58	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. Clinical Gastroenterology and Hepatology, 2018, 16, 1829-1831.	4.4	4
59	Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. American Journal of Gastroenterology, 2018, 113, 1516-1523.	0.4	47
60	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. Gastroenterology, 2018, 154, 1201-1202.	1.3	20
61	A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 191-197.	1.9	33
62	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus. Journal of Crohn's and Colitis, 2018, 12, 408-418.	1.3	102
63	Heterogeneity in Definitions of Efficacy and Safety EndpointsÂforÂClinical Trials of Crohn's Disease: AÂSystematicÂReview. Clinical Gastroenterology and Hepatology, 2018, 16, 1407-1419.e22.	4.4	41
64	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	12.1	108
65	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2018, 16, 637-647.e13.	4.4	44
66	A Web-based Multimedia Program Before Colonoscopy Increased Knowledge and Decreased Anxiety, Sedation Requirement, and Procedure Time. Journal of Clinical Gastroenterology, 2018, 52, 519-523.	2.2	19
67	Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease. , 2018, , 101-112.		0
68	Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems. Journal of Crohn's and Colitis, 2018, 12, 1499-1504.	1.3	5
69	Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care. American Journal of Gastroenterology, 2018, 113, 1440-1443.	0.4	18
70	Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology, 2018, 155, 1008-1011.e8.	1.3	56
71	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2461-2467.	1.9	50
72	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.4	119

#	Article	IF	CITATIONS
73	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn'sÂDisease. Gastroenterology, 2018, 155, 687-695.e10.	1.3	93
74	A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 1014-1020.	1.3	24
75	Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach. Current Drug Targets, 2018, 19, 740-747.	2.1	3
76	Fostering Collaboration Through Creation of an IBD Learning Health System. American Journal of Gastroenterology, 2017, 112, 406-408.	0.4	35
77	Transforming Gastroenterology Care With Telemedicine. Gastroenterology, 2017, 152, 958-963.	1.3	57
78	Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD. Inflammatory Bowel Diseases, 2017, 23, 570-577.	1.9	78
79	Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits. Inflammatory Bowel Diseases, 2017, 23, 1678-1681.	1.9	50
80	Quality Improvement Initiatives in Inflammatory Bowel Disease. Current Gastroenterology Reports, 2017, 19, 41.	2.5	18
81	Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium. Gastroenterology, 2017, 152, S371.	1.3	12
82	Beyond disease activity to overall disease severity in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2017, 2, 624-626.	8.1	5
83	Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 933-939.	1.9	4
84	Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflammatory Bowel Diseases, 2016, 22, 940-947.	1.9	29
85	Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. International Journal of Colorectal Disease, 2016, 31, 973-982.	2.2	23
86	Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation ofÂResults. Clinical Gastroenterology and Hepatology, 2016, 14, 1302-1309.	4.4	36
87	The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn's Disease: Results From the US VICTORY Consortium. American Journal of Gastroenterology, 2016, 111, 1147-1155.	0.4	257
88	Mo1846 Delivering High Value IBD Care Through Telemedicine Visits. Gastroenterology, 2016, 150, S792.	1.3	4
89	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 914-915.	4.4	0
90	Is the Hype of Medical Marijuana All Smoke and Mirrors?. American Journal of Gastroenterology, 2016, 111, 161-162.	0.4	3

#	Article	IF	CITATIONS
91	Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients' Perspectives on Shared Decision Making. Patient, 2016, 9, 79-89.	2.7	32
92	Increasing Patient Activation Could Improve Outcomes for Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2975-2978.	1.9	21
93	IBD LIVE Case Series—Case 3. Inflammatory Bowel Diseases, 2015, 21, 2958-2968.	1.9	7
94	Previous Cancer in a Patient with Crohn \hat{E} ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	2
95	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. Gastroenterology, 2015, 148, 344-354.e5.	1.3	226
96	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. Clinical Gastroenterology and Hepatology, 2015, 13, 2233-2240.e2.	4.4	109
97	Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 2636-2645.	2.3	34
98	Medical Marijuana for Digestive Disorders: High Time to Prescribe?. American Journal of Gastroenterology, 2015, 110, 208-214.	0.4	47
99	IBD LIVE Case Series—Case 1. Inflammatory Bowel Diseases, 2014, 20, 1696-1701.	1.9	4
100	The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. Inflammatory Bowel Diseases, 2014, 20, 1687-1695.	1.9	23
101	Patient Preferences for Surgical Versus Medical Therapy for Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 103-114.	1.9	67
102	Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. Gastroenterology, 2014, 146, 884-887.	1.3	5
103	Anti–Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD. Gastroenterology Clinics of North America, 2014, 43, 441-456.	2.2	20
104	Systematic review: monotherapy with antitumour necrosis factor \hat{I}_{\pm} agents versus combination therapy with an immunosuppressive for IBD. Gut, 2014, 63, 1843-1853.	12.1	106
105	Risks of Serious Infection or Lymphoma With Anti–Tumor NecrosisÂFactor Therapy for Pediatric Inflammatory Bowel Disease: AÂSystematic Review. Clinical Gastroenterology and Hepatology, 2014, 12, 1443-1451.	4.4	137
106	The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2014, 43, 525-541.	2.2	39
107	Translating Improved Quality of Care Into an Improved Quality of Life for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 908-912.	4.4	45
108	Do Inflammatory Bowel Disease Therapies Cause Cancer?. Inflammatory Bowel Diseases, 2013, 19, 1306-1321.	1.9	51

#	Article	IF	CITATIONS
109	Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2927-2936.	1.9	25
110	Challenges in IBD Research. Inflammatory Bowel Diseases, 2013, 19, 677-682.	1.9	31
111	Patient decision tools in inflammatory bowel disease. Gastroenterology and Hepatology, 2013, 9, 585-7.	0.1	0
112	Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut, 2012, 61, 459-465.	12.1	91
113	Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model. Clinical Gastroenterology and Hepatology, 2012, 10, 46-51.	4.4	45
114	Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2012, 41, 411-428.	2.2	7
115	Lymphoma risk in children and young adults with inflammatory bowel disease: Analysis of a large single-center cohort. Inflammatory Bowel Diseases, 2012, 18, 838-843.	1.9	50
116	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. American Journal of Gastroenterology, 2011, 106, 1594-1602.	0.4	71
117	Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflammatory Bowel Diseases, 2011, 17, 30-38.	1.9	72
118	The Impact of Ulcerative Colitis on Patients' Lives Compared to Other Chronic Diseases: A Patient Survey. Digestive Diseases and Sciences, 2010, 55, 1044-1052.	2.3	57
119	Improving quality of care in IBD: A STEEEP challenge. Inflammatory Bowel Diseases, 2010, 16, 134-136.	1.9	8
120	When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflammatory Bowel Diseases, 2010, 16, 1658-1662.	1.9	51
121	Lost in translation. Inflammatory Bowel Diseases, 2010, 16, 2168-2172.	1.9	24
122	Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management. Journal of Managed Care Pharmacy, 2010, 16, 616-628.	2.2	61
123	What Options Do We Have for Induction Therapy for Crohn's Disease?. Digestive Diseases, 2010, 28, 543-547.	1.9	6
124	The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. Clinical Gastroenterology and Hepatology, 2010, 8, 655-659.	4.4	46
125	Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Digestive and Liver Disease, 2010, 42, 777-784.	0.9	35
126	Patient's Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease. Digestion, 2009, 79, 30-35.	2.3	28

#	Article	IF	CITATIONS
127	Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology, 2009, 2, 245-251.	3.2	69
128	Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?. Risk Analysis, 2009, 29, 121-136.	2.7	38
129	Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 874-881.	4.4	459
130	Making therapeutic decisions in inflammatory bowel disease: the role of patients. Current Opinion in Gastroenterology, 2009, 25, 334-338.	2.3	26
131	Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008, 14, 1-6.	1.9	61
132	Crohn's Disease Patients' Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy. Gastroenterology, 2007, 133, 769-779.	1.3	167
133	Embracing the internet for progress in shared decision-making. Inflammatory Bowel Diseases, 2007, 13, 1579-1580.	1.9	17
134	Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1017-1024.	4.4	130
135	Risk factors for colorectal cancer in Crohn's colitis: A case-control study. Inflammatory Bowel Diseases, 2006, 12, 491-496.	1.9	46
136	As if mothers don't have enough to worry about…. Inflammatory Bowel Diseases, 2006, 12, 146-147.	1.9	1
137	Identifying and Predicting the Goals and Concerns of Individuals with Inflammatory Bowel Disease. SSRN Electronic Journal, O, , .	0.4	0
138	Bidirectional Correlations Between Health Confidence and Inflammatory Bowel Disease Activity: A Nationwide Longitudinal Cohort Study. Inflammatory Bowel Diseases, 0, , .	1.9	1